Morgan Stanley Reiterates Underweight on Genmab, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Underweight rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.
August 04, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has reiterated an Underweight rating on Genmab, maintaining a $33 price target.
The Underweight rating from Morgan Stanley suggests that the firm believes Genmab's stock is expected to underperform compared to other stocks. The maintained price target of $33 indicates that the firm does not expect significant price appreciation in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100